Arana Announces Resignation of CEO

View announcement at arana.com

Thursday, 06 November 2008 Sydney, Australia:
Biotechnology company Arana Therapeutics Limited (ASX: AAH) today announced the resignation of Chief Executive Officer and Managing Director John Chiplin.

Robin Beaumont, Chairman of Arana said: “We wish to thank John for his service and contribution to Arana Therapeutics over his three year tenure. John has led the company through a period of rapid change and significant progress, including the sale of Peptech’s Domantis shareholding, the successful merger last year of Peptech with EvoGenix and the rationalisation and focusing of the technology portfolio. The Board and John have now determined that this is an appropriate time to transition the CEO role and we will now focus on ensuring that his replacement will be the best available person to lead Arana in its next stage of development.”

The Board will be undertaking a search for a new CEO, as well as appointing an acting CEO. Announcements on these appointments will be made in due course.

Ends

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH) is an international biopharmaceutical company developing next generation drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics’ innovative protein engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline.

Arana has a significant track record of commercialising its technologies and has partnerships with GSK, CSL, Centocor (J&J) and Abbott Laboratories.

For further information: www.arana.com

For further information: www.arana.com

Contact information: